Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2026 06:10 ET | Source: Aura Minerals Inc

Aura Announces Receipt of the Construction License and Commencement of Early Works at the Era Dorada Project

AURA ANNOUNCES RECEIPT OF THE CONSTRUCTION LICENSE AND COMMENCEMENT OF EARLY WORKS AT THE ERA DORADA PROJECT
January 06, 2026 06:10 ET | Source: 22nd Century Group, Inc.

22nd Century Files VLN® MRTP Renewal – Only Combustible Tobacco Product Authorized by the FDA Specifically to Help Smokers Smoke Less

VLN® Reduced Nicotine Content Tobacco Reduces Smoking and Increases Quit Attempts Per Clinical Data Multiple VLN® Based Cigarette Brands Expand Availability and Reach of Non-Addictive Alternative in...
January 06, 2026 06:00 ET | Source: Apogee Therapeutics

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of...
January 06, 2026 06:00 ET | Source: Aclarion, Inc.

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data
January 06, 2026 06:00 ET | Source: Radware Ltd.

Radware Doubles Global Cloud Security Capacity

Cloud security service centers now equipped to mitigate up to 30 Tbps of attack volume Latest generation of DefensePro® X, Radware’s industry-leading DDoS mitigation platform allows for enhanced...
January 06, 2026 05:00 ET | Source: MoonFox Data

MoonFox Data | XPeng Motors’ Breakneck Run Continues, but Concentrated Lineup Risks Loom

XPeng Inc. (NYSE: XPEV; HKEX: 9868) reported strong Q3 2025 results—deliveries up 149.3% YoY to 116,007 units, revenue +101.8% YoY to RMB 20.38 billion.
January 06, 2026 05:00 ET | Source: Himax Technologies, Inc.

Himax and Vuzix to Introduce a Lightweight Prescription-Ready Optical Reference Design for AR Glasses at CES 2026

TAINAN, Taiwan and ROCHESTER, N.Y., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax”), a leading supplier and fabless manufacturer of display drivers and other...
January 06, 2026 04:00 ET | Source: Oculis Holding AG

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritisPrivosegtor is advancing...
January 06, 2026 04:00 ET | Source: Oculis Holding AG

Oculis tilkynnir um að Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hafi veitt Privosegtor stöðu byltingarkennds meðferðarlyfs til meðhöndlunar á sjóntaugabólgu

ZUG, Sviss, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Taugaverndandi þróunarlyfið Privosegtor hefur fengið stöðu byltingarkennds meðferðarlyfs (e. Breakthrough Therapy Designation) til meðhöndlunar á...
January 06, 2026 04:00 ET | Source: Oculis Holding AG

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is...